Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

EKSO vs IRBT vs CYBR vs NVCR vs ISRG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
EKSO
Ekso Bionics Holdings, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$29M
5Y Perf.-79.5%
IRBT
iRobot Corporation

Furnishings, Fixtures & Appliances

Consumer CyclicalNASDAQ • US
Market Cap$2M
5Y Perf.-99.9%
CYBR
CyberArk Software Ltd.

Software - Infrastructure

TechnologyNASDAQ • IL
Market Cap$20.64B
5Y Perf.+315.1%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-77.4%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+136.7%

EKSO vs IRBT vs CYBR vs NVCR vs ISRG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
EKSO logoEKSO
IRBT logoIRBT
CYBR logoCYBR
NVCR logoNVCR
ISRG logoISRG
IndustryMedical - Instruments & SuppliesFurnishings, Fixtures & AppliancesSoftware - InfrastructureMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$29M$2M$20.64B$1.92B$161.07B
Revenue (TTM)$12M$547M$1.36B$674M$10.58B
Net Income (TTM)$-16M$-209M$-147M$-173M$2.98B
Gross Margin52.9%22.0%74.3%75.2%66.3%
Operating Margin-134.1%-29.5%-7.7%-27.2%30.5%
Forward P/E81.9x43.8x
Total Debt$3M$227M$1.22B$290M$303M
Cash & Equiv.$1M$134M$623M$103M$3.37B

EKSO vs IRBT vs CYBR vs NVCR vs ISRGLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

EKSO
IRBT
CYBR
NVCR
ISRG
StockMay 20May 26Return
Ekso Bionics Holdin… (EKSO)10020.5-79.5%
iRobot Corporation (IRBT)1000.1-99.9%
CyberArk Software L… (CYBR)100415.1+315.1%
NovoCure Limited (NVCR)10022.6-77.4%
Intuitive Surgical,… (ISRG)100236.7+136.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: EKSO vs IRBT vs CYBR vs NVCR vs ISRG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ISRG leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Ekso Bionics Holdings, Inc. is the stronger pick specifically for dividend income and shareholder returns and recent price momentum and sentiment. CYBR also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
EKSO
Ekso Bionics Holdings, Inc.
The Income Pick

EKSO is the #2 pick in this set and the best alternative if dividends and momentum is your priority.

  • 0.8% yield; the other 4 pay no meaningful dividend
  • +79.3% vs IRBT's -97.7%
Best for: dividends and momentum
IRBT
iRobot Corporation
The Consumer Cyclical Pick

IRBT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: consumer cyclical exposure
CYBR
CyberArk Software Ltd.
The Income Pick

CYBR ranks third and is worth considering specifically for income & stability and growth exposure.

  • beta 0.92
  • Rev growth 36.0%, EPS growth -38.2%, 3Y rev CAGR 32.0%
  • 9.0% 10Y total return vs ISRG's 5.5%
  • 36.0% revenue growth vs EKSO's -28.6%
Best for: income & stability and growth exposure
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ISRG
Intuitive Surgical, Inc.
The Defensive Pick

ISRG carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.

  • Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
  • Beta 1.02, current ratio 4.87x
  • Better valuation composite
  • 28.2% margin vs EKSO's -135.7%
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthCYBR logoCYBR36.0% revenue growth vs EKSO's -28.6%
ValueISRG logoISRGBetter valuation composite
Quality / MarginsISRG logoISRG28.2% margin vs EKSO's -135.7%
Stability / SafetyCYBR logoCYBRBeta 0.92 vs IRBT's 5.21, lower leverage
DividendsEKSO logoEKSO0.8% yield; the other 4 pay no meaningful dividend
Momentum (1Y)EKSO logoEKSO+79.3% vs IRBT's -97.7%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs EKSO's -74.2%, ROIC 15.0% vs -88.1%

EKSO vs IRBT vs CYBR vs NVCR vs ISRG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

EKSOEkso Bionics Holdings, Inc.
FY 2023
Product
77.3%$14M
Service
15.4%$3M
Subscription
5.3%$967,000
Product and Service, Other
2.0%$359,000
IRBTiRobot Corporation
FY 2024
Reportable Segment
100.0%$682M
CYBRCyberArk Software Ltd.
FY 2024
Saas
46.8%$469M
Self Hosted Subscription
26.4%$265M
Maintenance and support
19.7%$197M
Professional services
5.6%$56M
Perpetual License
1.4%$14M
NVCRNovoCure Limited

Segment breakdown not available.

ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B

EKSO vs IRBT vs CYBR vs NVCR vs ISRG — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

ISRG is the larger business by revenue, generating $10.6B annually — 915.0x EKSO's $12M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to EKSO's -135.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricEKSO logoEKSOEkso Bionics Hold…IRBT logoIRBTiRobot CorporationCYBR logoCYBRCyberArk Software…NVCR logoNVCRNovoCure LimitedISRG logoISRGIntuitive Surgica…
RevenueTrailing 12 months$12M$547M$1.4B$674M$10.6B
EBITDAEarnings before interest/tax-$14M-$151M$23M-$165M$3.8B
Net IncomeAfter-tax profit-$16M-$209M-$147M-$173M$3.0B
Free Cash FlowCash after capex-$12M-$107M$259M-$48M$2.8B
Gross MarginGross profit ÷ Revenue+52.9%+22.0%+74.3%+75.2%+66.3%
Operating MarginEBIT ÷ Revenue-134.1%-29.5%-7.7%-27.2%+30.5%
Net MarginNet income ÷ Revenue-135.7%-38.2%-10.8%-25.7%+28.2%
FCF MarginFCF ÷ Revenue-103.4%-19.6%+19.0%-7.1%+26.8%
Rev. Growth (YoY)Latest quarter vs prior year-36.6%-24.6%+18.5%+12.3%+23.0%
EPS Growth (YoY)Latest quarter vs prior year-17.5%-195.2%+83.2%-100.0%+18.8%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ISRG leads this category, winning 3 of 6 comparable metrics.

On an enterprise value basis, ISRG's 43.6x EV/EBITDA is more attractive than CYBR's 908.2x.

MetricEKSO logoEKSOEkso Bionics Hold…IRBT logoIRBTiRobot CorporationCYBR logoCYBRCyberArk Software…NVCR logoNVCRNovoCure LimitedISRG logoISRGIntuitive Surgica…
Market CapShares × price$29M$2M$20.6B$1.9B$161.1B
Enterprise ValueMkt cap + debt − cash$30M$95M$21.2B$2.1B$158.0B
Trailing P/EPrice ÷ TTM EPS-2.40x-0.01x-139.54x-13.80x57.62x
Forward P/EPrice ÷ next-FY EPS est.81.87x43.84x
PEG RatioP/E ÷ EPS growth rate2.65x
EV / EBITDAEnterprise value multiple908.21x43.62x
Price / SalesMarket cap ÷ Revenue2.24x0.00x15.16x2.92x16.00x
Price / BookPrice ÷ Book value/share3.17x0.03x8.54x5.51x9.17x
Price / FCFMarket cap ÷ FCF79.60x64.67x
ISRG leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 7 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-177 for EKSO. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRBT's 3.71x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs CYBR's 3/9, reflecting solid financial health.

MetricEKSO logoEKSOEkso Bionics Hold…IRBT logoIRBTiRobot CorporationCYBR logoCYBRCyberArk Software…NVCR logoNVCRNovoCure LimitedISRG logoISRGIntuitive Surgica…
ROE (TTM)Return on equity-177.4%-112.9%-6.1%-50.8%+16.9%
ROA (TTM)Return on assets-74.2%-43.3%-3.0%-16.5%+14.8%
ROICReturn on invested capital-88.1%-38.6%-3.2%-16.4%+15.0%
ROCEReturn on capital employed-87.1%-27.7%-3.3%-28.9%+16.5%
Piotroski ScoreFundamental quality 0–933356
Debt / EquityFinancial leverage0.29x3.71x0.51x0.85x0.02x
Net DebtTotal debt minus cash$1M$93M$599M$187M-$3.1B
Cash & Equiv.Liquid assets$1M$134M$623M$103M$3.4B
Total DebtShort + long-term debt$3M$227M$1.2B$290M$303M
Interest CoverageEBIT ÷ Interest expense-20.44x-3.36x-96.80x
ISRG leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CYBR leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in CYBR five years ago would be worth $34,006 today (with dividends reinvested), compared to $6 for IRBT. Over the past 12 months, EKSO leads with a +79.3% total return vs IRBT's -97.7%. The 3-year compound annual growth rate (CAGR) favors CYBR at 43.4% vs IRBT's -88.8% — a key indicator of consistent wealth creation.

MetricEKSO logoEKSOEkso Bionics Hold…IRBT logoIRBTiRobot CorporationCYBR logoCYBRCyberArk Software…NVCR logoNVCRNovoCure LimitedISRG logoISRGIntuitive Surgica…
YTD ReturnYear-to-date+50.5%-55.0%-6.1%+28.3%-19.3%
1-Year ReturnPast 12 months+79.3%-97.7%+13.3%+1.1%-15.4%
3-Year ReturnCumulative with dividends-49.9%-99.9%+194.8%-75.7%+49.6%
5-Year ReturnCumulative with dividends-85.5%-99.9%+240.1%-91.3%+58.7%
10-Year ReturnCumulative with dividends-99.3%-99.9%+901.8%+30.3%+554.2%
CAGR (3Y)Annualised 3-year return-20.6%-88.8%+43.4%-37.6%+14.4%
CYBR leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — EKSO and CYBR each lead in 1 of 2 comparable metrics.

CYBR is the less volatile stock with a 0.92 beta — it tends to amplify market swings less than IRBT's 5.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EKSO currently trades 87.4% from its 52-week high vs IRBT's 0.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricEKSO logoEKSOEkso Bionics Hold…IRBT logoIRBTiRobot CorporationCYBR logoCYBRCyberArk Software…NVCR logoNVCRNovoCure LimitedISRG logoISRGIntuitive Surgica…
Beta (5Y)Sensitivity to S&P 5002.02x5.21x0.92x2.20x1.02x
52-Week HighHighest price in past year$13.50$6.10$526.19$20.06$603.88
52-Week LowLowest price in past year$2.73$0.04$347.12$9.82$427.84
% of 52W HighCurrent price vs 52-week peak+87.4%+0.9%+77.7%+83.9%+75.1%
RSI (14)Momentum oscillator 0–10059.933.938.969.842.4
Avg Volume (50D)Average daily shares traded68K001.5M1.8M
Evenly matched — EKSO and CYBR each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: EKSO as "Buy", CYBR as "Buy", NVCR as "Buy", ISRG as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -49.2% for EKSO (target: $6). EKSO is the only dividend payer here at 0.79% yield — a key consideration for income-focused portfolios.

MetricEKSO logoEKSOEkso Bionics Hold…IRBT logoIRBTiRobot CorporationCYBR logoCYBRCyberArk Software…NVCR logoNVCRNovoCure LimitedISRG logoISRGIntuitive Surgica…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$6.00$459.00$33.50$622.60
# AnalystsCovering analysts4491555
Dividend YieldAnnual dividend ÷ price+0.8%
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS$0.09
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.0%0.0%+1.4%
Insufficient data to determine a leader in this category.
Key Takeaway

ISRG leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). CYBR leads in 1 (Total Returns). 1 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 3 of 6 categories
Loading custom metrics...

EKSO vs IRBT vs CYBR vs NVCR vs ISRG: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is EKSO or IRBT or CYBR or NVCR or ISRG a better buy right now?

For growth investors, CyberArk Software Ltd.

(CYBR) is the stronger pick with 36. 0% revenue growth year-over-year, versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 6x trailing P/E (43. 8x forward), making it the more compelling value choice. Analysts rate Ekso Bionics Holdings, Inc. (EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — EKSO or IRBT or CYBR or NVCR or ISRG?

On forward P/E, Intuitive Surgical, Inc.

is actually cheaper at 43. 8x.

03

Which is the better long-term investment — EKSO or IRBT or CYBR or NVCR or ISRG?

Over the past 5 years, CyberArk Software Ltd.

(CYBR) delivered a total return of +240. 1%, compared to -99. 9% for iRobot Corporation (IRBT). Over 10 years, the gap is even starker: CYBR returned +901. 8% versus IRBT's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — EKSO or IRBT or CYBR or NVCR or ISRG?

By beta (market sensitivity over 5 years), CyberArk Software Ltd.

(CYBR) is the lower-risk stock at 0. 92β versus iRobot Corporation's 5. 21β — meaning IRBT is approximately 468% more volatile than CYBR relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 4% for iRobot Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — EKSO or IRBT or CYBR or NVCR or ISRG?

By revenue growth (latest reported year), CyberArk Software Ltd.

(CYBR) is pulling ahead at 36. 0% versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). On earnings-per-share growth, the picture is similar: iRobot Corporation grew EPS 55. 3% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Over a 3-year CAGR, CYBR leads at 32. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — EKSO or IRBT or CYBR or NVCR or ISRG?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -91. 4% for Ekso Bionics Holdings, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -104. 1% for EKSO. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is EKSO or IRBT or CYBR or NVCR or ISRG more undervalued right now?

On forward earnings alone, Intuitive Surgical, Inc.

(ISRG) trades at 43. 8x forward P/E versus 81. 9x for CyberArk Software Ltd. — 38. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — EKSO or IRBT or CYBR or NVCR or ISRG?

In this comparison, EKSO (0.

8% yield) pays a dividend. IRBT, CYBR, NVCR, ISRG do not pay a meaningful dividend and should not be held primarily for income.

09

Is EKSO or IRBT or CYBR or NVCR or ISRG better for a retirement portfolio?

For long-horizon retirement investors, CyberArk Software Ltd.

(CYBR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92), +901. 8% 10Y return). iRobot Corporation (IRBT) carries a higher beta of 5. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYBR: +901. 8%, IRBT: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between EKSO and IRBT and CYBR and NVCR and ISRG?

These companies operate in different sectors (EKSO (Healthcare) and IRBT (Consumer Cyclical) and CYBR (Technology) and NVCR (Healthcare) and ISRG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EKSO is a small-cap quality compounder stock; IRBT is a small-cap quality compounder stock; CYBR is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. EKSO pays a dividend while IRBT, CYBR, NVCR, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

EKSO

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 31%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

IRBT

Quality Business

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Gross Margin > 13%
Run This Screen
Stocks Like

CYBR

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Gross Margin > 44%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform EKSO and IRBT and CYBR and NVCR and ISRG on the metrics below

Revenue Growth>
%
(EKSO: -36.6% · IRBT: -24.6%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.